$EHC

Encompass Health Corp (EHC) Chief Accounting Officer Andrew Pric

Encompass Health Corp (EHC) Chief Accounting Officer Andrew Price sold 5,211 shares at $120.93 each, totaling $630,000, leaving him with 69,483 shares. This follows a year of insider selling with no buying, raising questions about near-term prospects. The stock is fairly valued, trading 4.8% above its GF Value estimate.

Original reporting
Published Sep 2, 2026, 4:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EHC
Bearish
medium confidence
Mentioned
$EHC
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$EHCBearishLow
01

Why it matters

Insider selling adds a modest bearish nuance to an otherwise fairly valued stock; investors may monitor for further insider activity.

02

Market read

The filing is a routine Form 4 disclosure; its impact is limited to EHC shareholders and short‑term sentiment.

03

What to watch

Recent earnings beat and stable valuation could offset the negative signal from insider selling.

Relevance 4/10Novelty 3/10Timing: post‑sale on Aug 31, 2026

Background

Encompass Health Corp (EHC) is a national post‑acute care provider with a market cap around $12 billion.

Company-level read

Ticker impact

$EHCBearishMedium confidence
Context

Chief Accounting Officer Andrew Price sold 5,211 shares at $120.93 each on Aug 31, 2026, reducing his stake to 69,483 shares.

Expected impact

Potential short‑term pressure on EHC shares as investors interpret the sale as reduced insider confidence.

Evidence & confidence

While the amount is relatively small for a mid‑cap, the lack of any insider buying and the cumulative sell‑off may weigh on sentiment.

Market effects

Adds to broader healthcare insider‑selling trends, but unlikely to shift sector sentiment.

Limited to U.S. healthcare investors; no broader regional effect.

Minimal; the news is company‑specific.

Counterpoint

The sale may be unrelated to confidence and driven by personal tax or liquidity needs, so it shouldn't be over‑weighted.

Key entities

  • Andrew Price

    Chief Accounting Officer of Encompass Health Corp

Related articles

$EHCHighAI 8/10

Encompass Health (EHC): This Rehab Hospital Giant Just Raised Its Own Bar Again

Encompass Health (EHC) reported Q2 revenue of $1.597B, up 9.6%, and adjusted EPS of $1.55, up 10.7%. The company raised full-year guidance for revenue, EBITDA, and EPS. It also increased its stock repurchase authorization to $1B. Patient volume and revenue per discharge grew, but free cash flow fell due to higher capital spending. Long-term debt rose to $2.598B.

$EHCMedAI 8/10

Does Stronger EPS, Higher 2026 Targets, and Bigger Buybacks Change The Bull Case For Encompass Health (EHC)?

Encompass Health (EHC) reported adjusted EPS of $1.55, raised its 2026 outlook, and increased its share buyback program to $1B. The company plans to open new hospitals and add beds, signaling confidence in long-term demand. Analysts project $7.9B revenue and $806.1M earnings by 2029, a 22% upside from current prices. Labor shortages remain a key risk.

$EHCMedAI 8/10

Encompass Health (EHC) Q2 2026 Earnings Call Transcript

Encompass Health (EHC) reported Q2 2026 net operating revenue of $1.597B (+9.6% YoY), adjusted EBITDA of $348M (+9.2%), and adjusted EPS of $1.55 (+10.7%). Full-year 2026 guidance was raised: revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25. The company also increased its $1B share repurchase authorization.

$EHCMed

Encompass Health Named Top SMidCap Pick by TD Cowen

TD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.

$EHCMedAI 8/10

Encompass Health Lifts 2026 Outlook Amid Strong Q2

Encompass Health (EHC) reported Q2 results and raised 2026 guidance. Q2 revenue rose 9.6% to support adjusted EBITDA of $348 million (+9.2%) and adjusted EPS up 10.7%. Full-year 2026 net operating revenue is guided to $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, and adjusted EPS $6.02-$6.25.